#Israel #Protalix BioTherapeutics #Russell 2000 #Carmiel #Russell 3000

Protalix BioTherapeutics Granted Membership in Russell Indexes

On June 30, 2025, Protalix BioTherapeutics, Inc., a biopharmaceutical company known for its innovative approach in developing recombinant therapeutic proteins, announced that it has been officially added to the Russell 3000® and Russell 2000® indexes. This inclusion marks a significant achievement for the company and is effective following the U.S. market close on June 27, 2025, as part of the annual reconstitution of the Russell indexes.

The Russell indexes are vital as they present a comprehensive picture of the largest U.S. stocks, ranking them by total market capitalization. The Russell 3000® encompasses the 3,000 largest U.S. stocks, while the Russell 2000® focuses specifically on the small-cap segment, representing a critical benchmark for investors and fund managers. Currently, around $10.6 trillion in assets are benchmarked against Russell indexes, which demonstrates the substantial impact that membership can have on a company's visibility and investment potential.

Dror Bashan, the President and CEO of Protalix, expressed enthusiasm regarding this new milestone. He stated, "We are very pleased to be included in the Russell 3000 and Russell 2000 Indexes. We welcome the enhanced visibility provided by our inclusion in these indexes as we continue progressing on our strategic path." This sentiment underscores the relevance of index membership not only for market visibility but also for the potential growth opportunities it provides.

Protalix BioTherapeutics focuses on developing, producing, and commercializing therapeutic proteins through its unique ProCellEx® plant cell-based protein expression system. With this strategic approach, Protalix has already achieved significant regulatory milestones, including being the first company to secure FDA approval for a protein produced using a plant cell-based platform. Their first product, taliglucerase alfa, is developed in collaboration with Pfizer, designed for the treatment of Gaucher disease. Additionally, in May 2023, Protalix received approval for its second product, Elfabrio®, which isn't just a testament to their innovative capabilities but also highlights their commitment to addressing diverse therapeutic needs.

The company’s pipeline includes several promising candidates targeting prevalent medical conditions, such as PRX–115 for uncontrolled gout and PRX–119 for treating NETs-related diseases, showcasing the depth of innovation that Protalix aims to deliver.

The inclusion in the Russell indexes signifies a new level of recognition for Protalix, as it joins a prestigious list of companies that are leaders in their respective sectors. This recognition is vital, especially in a competitive industry where research and innovation are constants. Furthermore, the anticipated visibility can potentially attract more institutional investors, amplify investor confidence, and positively impact stock performance in the long term.

As Protalix moves forward, the biopharmaceutical company is likely to leverage this enhanced profile to secure additional partnerships and foster growth within the biopharmaceutical market. This moment serves as a reminder of the dynamic nature of biopharmaceutical development, wherein innovative companies can rapidly gain prominence through dedication to research and breakthrough technologies.

In a sector characterized by complexity and constant change, the ability to adapt and thrive is critical. Protalix BioTherapeutics, through its strategic decisions and commitment to developing unique therapeutic solutions, exemplifies this agility. Its recent addition to the Russell 3000 and 2000 index not only elevates its market presence but also builds momentum toward future advancements in healthcare solutions.

As we look to the future, all eyes will be on Protalix as it continues to innovate and potentially reshape the landscape of biopharmaceuticals. With the backing of recognized indexes and the dedication of its leadership, Protalix is on a promising path forward that advocates for patients in need of unique and effective therapeutic options.